This action might not be possible to undo. Are you sure you want to continue?
Biocon is India's leading biotechnology enterprise. Biocon is India's first biotechnology company established in November 29,
It·s headquarters is in Bangalore ,India.
It·s CEO and MD is Kiran Mazumdar Shaw. The company serves partners and customers in over 50 countries. Within the biotechnology space, the company ranks 1st in Asia in terms of revenues and market capitalization and 16th globally.
Biocon is the country's first biotechnology company to export microbial enzymes to USA and Europe. Biocon is the first biotechnology company to receive ISO in India.
Biocon is the first company to manufacture insulin using a Pichia expression system Biocon became the first Indian biotech company to receive US funding for proprietary technologies. In 1993, Biocon's R&D and manufacturing facilities received ISO 9001 certification.
Launched India's 1st cancer drug BLOMAb EGFR. India·s largest producer and exporter of enzymes. 2 Indian company to cross the US $ 1 bn mark on the day of listing.
Products & Services
Biopharmaceuticals Enzymes Custom research Clinical research
INDIAN VALUES AND MANAGEMENT PHILOSOPHY Biocon's success has been characterized by an enduring set of corporate values based on ::Innovation Integrity Strong leadership Social responsibility
The company mission is to 'Develop novel & affordable Biotherapeutics for global markets'. ´Earn as you learn.µ For 25 years this unofficial philosophy had served Biocon well. Starting out in the enzyme business in 1978, the BangaloreBangalorebased firm had gradually expanded into the pharmaceutical industry.
It·s recently developed capabilities and the political, biological, intellectual, and financial benefits of the Indian environment to move into new areas of opportunity. The company applies its proprietary fermentation technologies to make effective and innovative biomolecules in diabetology, oncology, cardiology and other therapeutic segments.
With its strong focus on R&D In custom research (Syngene) in the fields of synthetic chemistry and molecular biology in early stage drug discovery and development. Clinical research (Clinigene) is carried out in the fields of clinical studies and clinical trials.
The Innovation Matrix: A Strategic Framework To navigate the challenges of innovation in the next decade we have adopted a well-defined wellstrategic framework that will transform scientific discoveries into advances in human healthcare and generate incremental value for our shareholders.
Biocon's integrated business approach has enabled the company to establish a significant presence in the global biopharmaceutical market via its product offerings and customized, high value solutions at any stage in the lifecycle of a drug from discovery to market. Biocon·s vision is to be an integrated biopharmaceutical enterprise of global distinction.
"Our ability to continuously scale new heights across the biopharmaceutical value chain enables us to realize the promise of future therapeutics." -Kiran MazumdarMazumdar-Shaw, Chairman & Managing Director.
Biocon is thus rapidly moving towards commercializing novel biologics with a "Made in India" label.
As India's first and leading biotechnology company Biocon extends its support to numerous community outreach and corporate citizenship initiatives with special concentration in the areas of healthcare, education and environment. The Biocon Foundation, set up in 2004 has launched Arogya Raksha Yojana, a unique health initiative for rural India.